| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38893102P | 2002-06-14 | 2002-06-14 | |
| US60/388,931 | 2002-06-14 | ||
| US10/294,310 | 2002-11-14 | ||
| US10/294,310US7146209B2 (en) | 2000-05-08 | 2002-11-14 | Stimulation for treating eye pathologies |
| PCT/IL2003/000508WO2003105658A2 (en) | 2002-06-14 | 2003-06-13 | Methods and systems for management of alzheimer's disease |
| Publication Number | Publication Date |
|---|---|
| AU2003241131A1true AU2003241131A1 (en) | 2003-12-31 |
| AU2003241131A8 AU2003241131A8 (en) | 2003-12-31 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003241131AAbandonedAU2003241131A1 (en) | 2002-06-14 | 2003-06-13 | Methods and systems for management of alzheimer's disease |
| Country | Link |
|---|---|
| EP (1) | EP1521614A2 (en) |
| AU (1) | AU2003241131A1 (en) |
| CA (1) | CA2489341A1 (en) |
| WO (1) | WO2003105658A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2408097A1 (en) | 2000-05-08 | 2001-11-15 | Brainsgate Ltd. | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
| US7146209B2 (en) | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
| US7117033B2 (en) | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
| US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
| US7561919B2 (en) | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
| DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US7499748B2 (en) | 2005-04-11 | 2009-03-03 | Cardiac Pacemakers, Inc. | Transvascular neural stimulation device |
| US7616990B2 (en)* | 2005-10-24 | 2009-11-10 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
| US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
| EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| US7965180B2 (en) | 2006-09-28 | 2011-06-21 | Semiconductor Energy Laboratory Co., Ltd. | Wireless sensor device |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
| EP2868299B1 (en) | 2009-08-24 | 2022-08-10 | New Phase Ltd | Phase change and shape change materials |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| CA2968648C (en) | 2014-11-25 | 2021-05-18 | New Phase Ltd. | Phase-change nanoparticle for treating cancerous cells |
| US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| AU2018277333B2 (en)* | 2017-05-30 | 2021-09-16 | Morinaga Milk Industry Co., Ltd. | Composition for improving brain function |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287793B1 (en) | 1988-08-19 | 2001-09-11 | Elan Pharmaceuticals, Inc. | Diagnostic methods for alzheimer's disease |
| US5735817A (en)* | 1995-05-19 | 1998-04-07 | Shantha; T. R. | Apparatus for transsphenoidal stimulation of the pituitary gland and adjoining brain structures |
| US6325475B1 (en)* | 1996-09-06 | 2001-12-04 | Microfab Technologies Inc. | Devices for presenting airborne materials to the nose |
| US6338715B1 (en)* | 1999-03-31 | 2002-01-15 | Microfab Technologies, Inc. | Digital olfactometer and method for testing olfactory thresholds |
| Publication number | Publication date |
|---|---|
| CA2489341A1 (en) | 2003-12-24 |
| EP1521614A2 (en) | 2005-04-13 |
| WO2003105658A2 (en) | 2003-12-24 |
| WO2003105658A3 (en) | 2004-03-18 |
| AU2003241131A8 (en) | 2003-12-31 |
| Publication | Publication Date | Title |
|---|---|---|
| AU2003241131A1 (en) | Methods and systems for management of alzheimer's disease | |
| EP1575527A3 (en) | Medical information management system and method | |
| AU2003249716A1 (en) | Method and system for increasing the efficacy of a clinical trial | |
| AU2003234591A1 (en) | Database system and methods | |
| AU2003284968A1 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
| AU2002357340A1 (en) | Method and system for integrated asset management | |
| AU2002311571A1 (en) | Methods and systems for management of information related to the appearance of an object | |
| AU2003284878A1 (en) | Systems and methods for clinical trials information management | |
| AU2002359427A1 (en) | Integrated intellectual asset management system and method | |
| AU2003274641A1 (en) | System and method for the optimization of database | |
| AU2002312066A1 (en) | Health care management system and method | |
| AU2003262065A1 (en) | Database re-organizing system and database | |
| AU2003216143A1 (en) | Configuration management method and system | |
| AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| AU2003261961A1 (en) | Medical information management system | |
| AU2003223579A1 (en) | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease | |
| AU2003283852A1 (en) | Managing metadata and system thereof | |
| AU2003220096A1 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
| AU2003295572A1 (en) | Value innovation management system and methods | |
| AU2003259909A1 (en) | Method and system for states of beings configuration management | |
| AU2003293135A1 (en) | System and method for managing investment information | |
| AU2003230667A1 (en) | Medical management system and method | |
| AU2003303141A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| AU2002336999A1 (en) | Model of autoimmune disease and methods for identifying agents against autoimmune disease | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease |
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |